Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13472446 | 0.83 | MAPT (0.43) | ALDH1A1CYP1A2KDM4EHPGDHSD17B10 | |
| SCHEMBL28855951 | 0.83 | ALDH1A1 (0.43) | ALDH1A1CYP1A2KDM4EHPGDHSD17B10 | |
| SCHEMBL13472458 | 0.83 | ALDH1A1 (0.43) | ALDH1A1CYP1A2KDM4EHPGDHSD17B10 | |
| SCHEMBL12590801 | 0.81 | CYP1A2 (0.42) | ALDH1A1CYP1A2KDM4EHPGDHSD17B10 | |
| SCHEMBL28936237 | 0.80 | ALDH1A1 (0.53) | ALDH1A1CYP1A2KDM4EHPGDHSD17B10 | |
| SCHEMBL13472476 | 0.80 | KDM4E (0.47) | ALDH1A1CYP1A2KDM4EHPGDHSD17B10 | |
| SCHEMBL5226806 | 0.78 | ALDH1A1 (0.44) | ALDH1A1CYP1A2KDM4EHPGDHSD17B10 | |
| SCHEMBL20187440 | 0.76 | KDM4E (0.51) | ALDH1A1CYP1A2KDM4EHPGDHSD17B10 | |
| SCHEMBL2843820 | 0.75 | ALDH1A1 (0.59) | ALDH1A1CYP1A2KDM4EHPGDHSD17B10 | |
| SCHEMBL29642902 | 0.75 | RAB9A (0.55) | ALDH1A1CYP1A2KDM4ELMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362100-B1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-10729738-B2 | Hindered disulfide drug conjugates | GENENTECH, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2017064675-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| EP-2308874-B1 | Bridged monobactams useful as beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| EP-2484680-A1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | Basilea Pharmaceutica AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| EP-1965798-B1 | USEFUL MONOBACTAM ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-10-19 | — | — | EP | disclosed |
| EP-2308874-A1 | Useful beta-lactamase inhibitors | Basilea Pharmaceutica AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1965798-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | Basilea Pharmaceutica AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007065288-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | ALDH1A1 2194/4885CYP1A2 624/4885KDM4E 1074/4885 |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | ALDH1A1 2194/4885CYP1A2 624/4885KDM4E 1074/4885 |
| US-10729738-B2 | Hindered disulfide drug conjugates | STS, TST, SCLY | ALDH1A1 143/4885CYP1A2 320/4885KDM4E 3411/4885 |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | MGAM, MGAM2, B2M | ALDH1A1 2423/4885CYP1A2 637/4885KDM4E 1140/4885 |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | STS, TST, SCLY | ALDH1A1 143/4885CYP1A2 320/4885KDM4E 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.